The Sanofi, Amgen, Alphabet, Novartis and PPD-backed clinical trials software producer is joining forces with publicly listed LifeSci Acquisition II Corp.
Science 37, a US-based clinical trials technology provider backed by corporates Sanofi, Amgen, Alphabet, Novartis and PPD, agreed on Friday to a reverse merger with special purpose acquisition company LifeSci Acquisition II Corp.
The transaction will involve the Science 37 taking the position on the Nasdaq Capital Market, taken by LifeSci Acquisition II Corp in a $75m initial public offering in November 2020. It will give Science 37 an initial enterprise value of about $1.05bn.
Science 37’s technology helps…
